

The Neurology Center of Southern California
6010 Hidden Valley Road, Ste. 200, Carlsbad, CA 92011
1955 Citracado Pkwy, Ste. 102, Escondido, CA 92029
Phone: 760-631-3000 Fax: 760-631-3016



Tara Quesnell, D.O.

EDUCATION

| | |
|--|---|
| Neurophysiology Fellowship University of Kansas Medical Center Kansas City, KS | 08/2014- 07/2015 |
| Neurology Residency University of Kansas Medical Center Kansas City, KS | 07/2011- 07/2014 |
| Internal Medicine Internship University of Kansas Medical Center Kansas City, KS | 07/2010- 06/2011 |
| Doctor of Osteopathic Medicine (D.O.) Kansas City University of Medicine and Biosciences Kansas City, MO | 08/2006- 05/2010 |
| Bachelors of Science (B.S) University of California, Santa Barbara Santa Barbara, CA | Microbiology, 06/2004 Minor in Classics, 06/2004 |

LICENSURE & CERTIFICATION

| | |
|--|-------------------|
| American Board of Psychiatry and Neurology- Neurology Certificate #58998 | 09/2014 - Present |
| American Board of Psychiatry and Neurology- Clinical Neurophysiology Certificate #2741 | 10/2015 - Present |
| NIH Stroke Scale certified | 07/2011- 2021 |
| Osteopathic Physician and Surgeon 20A, Osteopathic Medical board of California, # 20A13609 | |

AWARDS

San Diego County Medical Society/ San Diego Magazine Top Doctor: Clinical Neurophysiology
10/2021
American Academy of Neurology Medical Student Prize for Excellence in Neurology 03/2010

Tara Quesnell, D.O.

PROFESSIONAL SOCIETIES

American Academy of Neurology

PROFESSIONAL EXPERIENCE

Chief Operating Officer

Private Group Practice, North County Neurology Associates 04/2022- Present

Neurologist

North County Neurology Associates 09/2016- Present

Clinical Assistant Professor

The University of Kansas Hospital Neurology 08/2015- 08/2016
 University of Kansas School of Medicine
 University of Kansas Medical Center
 Rehabilitation Hospital of Overland Park

AHA Basic Life Support Instructor, Missouri

08/2008- 03/2009

Quest Diagnostics, California

10/2005- 07/2006

Laboratory Technician, Hematology and Chemistry Departments

Sansum Santa Barbara Medical Foundation Clinic, California

07/2004- 09/2005

Laboratory Assistant, Specimen processing and Microbiology Department

HOSPITAL AFFILIATIONS

Tri-City Medical Center, Oceanside, California 10/2016 – Present

Scripps Memorial Hospital, Encinitas, California 09/2016 – Present

Scripps Mercy Hospital, Chula Vista, California 08/2022 - Present

Palomar Medical Center, Escondido, California 09/2017 – Present

Palomar Medical Center, Poway, California 09/2017 – Present

PRESENTATIONS

American Academy of Neurology

4/2015 Poster presentation: Utility of screening for monoclonal gammopathy in ALS

Carrell-Krusen Neuromuscular Symposium

2/2015 Platform presentation: Utility of screening for monoclonal gammopathy in ALS

2/2015 Poster presentation: Two cases of unusual CIDP variants

KUMC Resident, Postdoc, & Fellow Research Forum

5/2015 Oral presentation: Utility of screening for monoclonal gammopathy in ALS

RESEARCH

Alzheimer's Disease

I5T-MC-AACI Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease. Sub-Investigator – 2023

JIG-MC-LAKC. Assessment of safety and efficacy measured by amyloid reduction of LY3372993 in early symptomatic AD. Sub-Investigator – 2023

Migraine

A Parallel Group Double Blind Randomized Placebo- Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine. Protocol Number: ALD403-CLIN-015. Sub-Investigator – 2019

Multiple Sclerosis

BN42082: A phase IIIB multicenter, randomized double blind, controlled study to evaluate the efficacy, safety and pharmacokinetics of a higher dose of Ocrelizumab in adults with relapsing multiple sclerosis. Sub-Investigator - 2019

GN41851. A phase III multicenter, randomized, double blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Fenebrutinib compared with Teriflunomide in adult patients with relapsing Multiple Sclerosis. Sub-Investigator - 2020

GN41791: a phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of fenebrutinib compared with ocrelizumab in adult patients with primary progressive multiple sclerosis. Sub-Investigator - 2022

Myasthenia Gravis

ARGX-113-1704. A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Weakness. Sub-Investigator – 2019

ARGX-113-1705. A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle Weakness. Sub-Investigator – 2020

RVT-1401-2002. A Phase 2a, Multicenter, Randomized, Double Blind, Placebo-Controlled Study with an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients. Sub-Investigator – 2020

MG-001- Autologous T-cells expressing a chimeric antigen receptor directed to B-cell maturation antigen (BCMA) in patients with generalized myasthenia gravis (MG) Sub-Investigator - 2021

ARGX-113-2001 A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC With Multiple Intravenous Infusions of Efgartigimod in Patients With Generalized Myasthenia Gravis. Sub-Investigator 2021

ARGX-113-2002 A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. Sub-Investigator 2021

ARGX-113-2003 A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis. Sub-Investigator 2021

IMVT-1401-3101 A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG)- Sub-Investigator 2022

Other

ARGX-113-1802. A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Sub-Investigator – 2020

ARGX-113-1902. Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Sub-Investigator – 2020

Synuclein-One Study – Sub Investigator 2021

IMVT-1401-2401: A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sub Investigator – 2023

IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) Sub Investigator – 2023

Department of Neurology Research Day

6/2014 Status epilepticus in an adult secondary to influenza A H1N1 and review of the neurological manifestations of H1N1 in Adults

6/2013 The role of neuroimaging in the management of the post rtPA acute stroke patient

6/2012 Sensory neuronopathy

University of California, Santa Barbara Department of Chemistry and Biochemistry
Undergraduate Researcher, Norbert Reich, Ph.D

Engineered four-way DNA junction components of DNA/ nano-particle constructs

2/2003 – 6/2004